Jeff Garro
Stock Analyst at Stephens & Co.
(0.95)
# 4,005
Out of 5,182 analysts
62
Total ratings
37.5%
Success rate
-12.41%
Average return
Main Sectors:
Stocks Rated by Jeff Garro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBRG TruBridge | Maintains: Equal-Weight | $20 → $18 | $25.83 | -30.31% | 4 | Apr 1, 2026 | |
| PHR Phreesia | Maintains: Overweight | $32 → $20 | $10.17 | +96.66% | 10 | Mar 31, 2026 | |
| HCAT Health Catalyst | Maintains: Equal-Weight | $3.5 → $2 | $1.52 | +31.58% | 5 | Mar 13, 2026 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $17 → $10 | $6.44 | +55.28% | 5 | Mar 6, 2026 | |
| DH Definitive Healthcare | Maintains: Equal-Weight | $3 → $2 | $0.95 | +109.93% | 2 | Feb 27, 2026 | |
| CERT Certara | Maintains: Overweight | $15 → $12 | $6.31 | +90.17% | 6 | Dec 12, 2025 | |
| PRVA Privia Health Group | Reiterates: Overweight | $32 | $23.06 | +38.77% | 6 | Dec 4, 2025 | |
| EVH Evolent Health | Reiterates: Equal-Weight | $9 | $4.18 | +115.31% | 6 | Sep 24, 2025 | |
| SLP Simulations Plus | Maintains: Overweight | $28 → $20 | $16.68 | +19.90% | 2 | Jul 15, 2025 | |
| VEEV Veeva Systems | Reiterates: Overweight | $280 | $166.34 | +68.33% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $55 | $25.98 | +111.70% | 1 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $250 | $178.71 | +39.89% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $18.81 | -9.62% | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $28 | $7.25 | +286.21% | 2 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $17.93 | +11.54% | 3 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $5 → $3.9 | $7.57 | -48.48% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $1.12 | +167.86% | 3 | May 6, 2022 |
TruBridge
Apr 1, 2026
Maintains: Equal-Weight
Price Target: $20 → $18
Current: $25.83
Upside: -30.31%
Phreesia
Mar 31, 2026
Maintains: Overweight
Price Target: $32 → $20
Current: $10.17
Upside: +96.66%
Health Catalyst
Mar 13, 2026
Maintains: Equal-Weight
Price Target: $3.5 → $2
Current: $1.52
Upside: +31.58%
OptimizeRx
Mar 6, 2026
Maintains: Equal-Weight
Price Target: $17 → $10
Current: $6.44
Upside: +55.28%
Definitive Healthcare
Feb 27, 2026
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $0.95
Upside: +109.93%
Certara
Dec 12, 2025
Maintains: Overweight
Price Target: $15 → $12
Current: $6.31
Upside: +90.17%
Privia Health Group
Dec 4, 2025
Reiterates: Overweight
Price Target: $32
Current: $23.06
Upside: +38.77%
Evolent Health
Sep 24, 2025
Reiterates: Equal-Weight
Price Target: $9
Current: $4.18
Upside: +115.31%
Simulations Plus
Jul 15, 2025
Maintains: Overweight
Price Target: $28 → $20
Current: $16.68
Upside: +19.90%
Veeva Systems
Mar 6, 2025
Reiterates: Overweight
Price Target: $280
Current: $166.34
Upside: +68.33%
Dec 20, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $25.98
Upside: +111.70%
Dec 20, 2024
Initiates: Overweight
Price Target: $250
Current: $178.71
Upside: +39.89%
Dec 9, 2024
Initiates: Buy
Price Target: $17
Current: $18.81
Upside: -9.62%
Jul 26, 2023
Reiterates: Equal-Weight
Price Target: $28
Current: $7.25
Upside: +286.21%
Aug 5, 2022
Maintains: Overweight
Price Target: $15 → $20
Current: $17.93
Upside: +11.54%
May 11, 2022
Maintains: Underweight
Price Target: $5 → $3.9
Current: $7.57
Upside: -48.48%
May 6, 2022
Maintains: Neutral
Price Target: $4 → $3
Current: $1.12
Upside: +167.86%